Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)
China · Delayed Price · Currency is CNY 14.16
+0.10 (0.71%)
Apr 28, 2026, 3:04 PM CST
SHE:300601 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,647 | 2,661 | 2,643 | 3,467 | 3,129 | 3,650 |
Other Revenue | 12.17 | 12.17 | 8.88 | 10.9 | 28.11 | 2.33 |
| 2,659 | 2,673 | 2,652 | 3,477 | 3,157 | 3,652 | |
Revenue Growth (YoY) | -6.55% | 0.81% | -23.75% | 10.14% | -13.54% | 61.51% |
Cost of Revenue | 819.14 | 808 | 700.7 | 655.29 | 775.09 | 1,148 |
Gross Profit | 1,840 | 1,865 | 1,951 | 2,822 | 2,382 | 2,504 |
Selling, General & Admin | 1,213 | 1,202 | 1,253 | 1,505 | 1,315 | 819.8 |
Research & Development | 507.07 | 543.42 | 508.12 | 500.75 | 801.86 | 354.26 |
Other Operating Expenses | 46.85 | 36.1 | 30.55 | 25.62 | 20.49 | 20.16 |
Operating Expenses | 1,814 | 1,824 | 1,821 | 2,044 | 2,177 | 1,204 |
Operating Income | 26.24 | 41.44 | 129.98 | 778.26 | 205.13 | 1,300 |
Interest Expense | -119.04 | -119.03 | -124.12 | -113.71 | -108.97 | -54.51 |
Interest & Investment Income | 65.38 | 79.48 | 98.85 | 117.32 | 133.57 | 144.63 |
Currency Exchange Gain (Loss) | -1.46 | -1.46 | 0.21 | 0 | -1.82 | -0.35 |
Other Non Operating Income (Expenses) | -1.19 | -0.69 | -0.16 | -0.65 | -0.52 | -4.19 |
EBT Excluding Unusual Items | -30.07 | -0.27 | 104.76 | 781.22 | 227.38 | 1,386 |
Gain (Loss) on Sale of Investments | 12.89 | 5.29 | 1.38 | 0.19 | 3.18 | - |
Gain (Loss) on Sale of Assets | -0.75 | -0.93 | -8.42 | -1.35 | 0.13 | 0.03 |
Asset Writedown | 13.41 | -14.9 | -15.57 | -3.32 | -624.09 | -3.41 |
Other Unusual Items | 62.97 | 56.28 | 67.79 | 163.57 | 55.15 | 56.78 |
Pretax Income | 58.44 | 45.46 | 149.94 | 940.32 | -338.25 | 1,439 |
Income Tax Expense | -23.05 | -24.81 | -51.62 | 79.02 | -205.54 | 175.87 |
Earnings From Continuing Operations | 81.49 | 70.27 | 201.55 | 861.3 | -132.71 | 1,263 |
Minority Interest in Earnings | -0.25 | 0.06 | 0.1 | - | - | - |
Net Income | 81.24 | 70.33 | 201.65 | 861.3 | -132.71 | 1,263 |
Net Income to Common | 81.24 | 70.33 | 201.65 | 861.3 | -132.71 | 1,263 |
Net Income Growth | -52.22% | -65.12% | -76.59% | - | - | 86.01% |
Shares Outstanding (Basic) | 1,170 | 1,172 | 1,120 | 1,119 | 1,106 | 1,093 |
Shares Outstanding (Diluted) | 1,170 | 1,172 | 1,120 | 1,119 | 1,106 | 1,111 |
Shares Change (YoY) | 3.47% | 4.63% | 0.15% | 1.15% | -0.43% | 3.23% |
EPS (Basic) | 0.07 | 0.06 | 0.18 | 0.77 | -0.12 | 1.16 |
EPS (Diluted) | 0.07 | 0.06 | 0.18 | 0.77 | -0.12 | 1.14 |
EPS Growth | -53.82% | -66.67% | -76.62% | - | - | 80.18% |
Free Cash Flow | 245.6 | 303.65 | 131.07 | 314.65 | -764.7 | -888.15 |
Free Cash Flow Per Share | 0.21 | 0.26 | 0.12 | 0.28 | -0.69 | -0.80 |
Dividend Per Share | 0.035 | 0.035 | 0.090 | 0.380 | - | 0.719 |
Dividend Growth | -61.11% | -61.11% | -76.32% | - | - | 283.36% |
Gross Margin | 69.19% | 69.77% | 73.58% | 81.16% | 75.45% | 68.57% |
Operating Margin | 0.99% | 1.55% | 4.90% | 22.38% | 6.50% | 35.60% |
Profit Margin | 3.06% | 2.63% | 7.61% | 24.77% | -4.20% | 34.59% |
Free Cash Flow Margin | 9.24% | 11.36% | 4.94% | 9.05% | -24.22% | -24.32% |
EBITDA | 439.1 | 435.18 | 447.22 | 979.66 | 406.08 | 1,705 |
EBITDA Margin | 16.51% | 16.28% | 16.86% | 28.17% | 12.86% | 46.69% |
D&A For EBITDA | 412.86 | 393.73 | 317.24 | 201.39 | 200.95 | 404.71 |
EBIT | 26.24 | 41.44 | 129.98 | 778.26 | 205.13 | 1,300 |
EBIT Margin | 0.99% | 1.55% | 4.90% | 22.38% | 6.50% | 35.60% |
Effective Tax Rate | - | - | - | 8.40% | - | 12.22% |
Revenue as Reported | 2,659 | 2,673 | 2,652 | 3,477 | 3,157 | 3,652 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.